← Scoopfeeds — Intelligent news, curated.
Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?
business

Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?

Yahoo Finance · Jun 30, 2026, 1:06 PM · Also reported by 1 other source

Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates?

Read full story on Yahoo Finance → More top stories

Also covered by

MarketWatch Alphabet’s stock slump is a ‘tactical buying opportunity,’ according to one analyst

More in business

Decrypt
Sharplink Buys Ethereum for First Time in 2026—With ETH Down 68% From Peak
Decrypt
Dutch Prosecutors Seek to Bankrupt Crypto Platform Knaken After Funds Frozen
CNBC
GOP Rep. Tom Kean says depression diagnosis caused months-long absence from Congress
Investing.com
Why is Axon Enterprise stock surging today?
MarketWatch
Even Wall Street bulls are worried about a stock-market pullback after dazzling second quarter
Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop